Zimmer Biomet Holdings, Inc. (ZBH) Q4 2025 Earnings Call Transcript
Zimmer Biomet beats Q4 earnings and revenue estimates, with sales up 10.9% and shares rising 1.4% pre-market despite margin contraction.
The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
| Health Care Equipment & Supplies Industry | Healthcare Sector | Ivan Tornos CEO | XWBO Exchange | US98956P1021 ISIN |
| US Country | 17,000 Employees | 31 Mar 2026 Last Dividend | 1 Mar 2022 Last Split | 25 Jul 2001 IPO Date |
Zimmer Biomet Holdings, Inc., alongside its subsidiaries, is entrenched in the musculoskeletal healthcare sector, spreading its influence across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The enterprise is committed to designing, manufacturing, and marketing a comprehensive range of orthopaedic reconstructive products. Initially known as Zimmer Holdings, Inc., the organization underwent a rebranding to Zimmer Biomet Holdings, Inc. in June 2015, marking a significant milestone in its evolution since its inception in 1927. This rebranding reflects the company’s growth and its expanding portfolio in the musculoskeletal healthcare domain. Headquartered in Warsaw, Indiana, Zimmer Biomet has become a pivotal player in providing solutions for patients afflicted with disorders or injuries related to bones, joints, or supporting soft tissues. It caters to the needs of orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, and a broad spectrum of healthcare professionals and organizations worldwide.
Zimmer Biomet Holdings, Inc. offers a wide variety of products and services across several key areas in musculoskeletal healthcare: